# BCI Discovery Session 3 - Follow-up Email Summary

**Meeting:** BCI/Abacus Data Sources Discovery Session 3 (EDP & Interop)
**Date:** October 9, 2025
**Purpose:** Follow-up summary of Session 3 decisions and action items

## Decisions Made

1. **Broker Data Prioritization** - Decision maker: Team consensus
   - Treat as separate domain
   - Prioritize for 2026, not 2025

## Action Items

- ACTION: Confirm if Formulary data needed for CMS compliance and establish data availability | OWNER: Dominic/Dan B | DUE: TBD
- ACTION: Assess impact of unavailable historical formulary data | OWNER: Dan B | DUE: TBD
- ACTION: Evaluate completeness and compliance relevance of Carelon RX claims history | OWNER: Rich T | DUE: TBD
- ACTION: Confirm if CVS Caremark Rx Claims required for compliance | OWNER: Rich T | DUE: TBD
- ACTION: Share CVS Caremark Rx Claims mapping | OWNER: Dan B | DUE: TBD
- ACTION: Confirm format of BCI Simplr files to be sent to Abacus | OWNER: Kelly | DUE: TBD
- ACTION: Confirm data governance expectations and delivery method for sensitivity tags | OWNER: Dan B | DUE: TBD
- ACTION: Confirm if sensitivity data accessible directly from Snowflake tables | OWNER: Valli P | DUE: TBD
- ACTION: Provide Facets RDM mappings and descriptions for FM model standardization | OWNER: Dan B | DUE: TBD

## Open Questions

None explicitly stated in email summary

## Key Discussion Points

Email serves as formal follow-up documenting nine action items across five topic areas: Formulary, RX Claims, Simplr, Sensitivity Tags, and Facets RDM Tables
